198404-35-2 Usage
Uses
Used in Pharmaceutical Industry:
Pyrimidine, 5-(bromomethyl)-2-(trifluoromethyl)(9CI) is used as a key intermediate in the synthesis of new drugs for various therapeutic applications. Its unique structural features and functional groups enable the development of innovative pharmaceutical compounds with improved efficacy and selectivity.
Used in Organic Synthesis:
In the field of organic synthesis, Pyrimidine, 5-(bromomethyl)-2-(trifluoromethyl)(9CI) serves as a versatile building block for the construction of complex organic molecules. Its bromomethyl and trifluoromethyl groups facilitate various chemical reactions, allowing for the synthesis of a wide range of organic compounds with diverse properties and applications.
Used in Medicinal Chemistry:
Pyrimidine, 5-(bromomethyl)-2-(trifluoromethyl)(9CI) is utilized as a starting material in the design and synthesis of novel bioactive molecules with potential therapeutic benefits. Its unique structural features and functional groups enable the development of compounds with enhanced pharmacological properties, such as improved binding affinity, selectivity, and bioavailability.
Used in Material Science:
In the realm of material science, Pyrimidine, 5-(bromomethyl)-2-(trifluoromethyl)(9CI) is employed in the development of advanced materials and specialty chemicals. Its unique structural features and functional groups contribute to the creation of materials with specific properties, such as improved stability, reactivity, or selectivity, which can be applied in various industrial processes and applications.
Check Digit Verification of cas no
The CAS Registry Mumber 198404-35-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,8,4,0 and 4 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 198404-35:
(8*1)+(7*9)+(6*8)+(5*4)+(4*0)+(3*4)+(2*3)+(1*5)=162
162 % 10 = 2
So 198404-35-2 is a valid CAS Registry Number.
